Page 24 - Read Online

J Cancer Metastasis Treat 2019;5:5 I http://dx.doi.org/10.20517/2394-4722.2018.108 Page 19 of 27
3 Pathology, IRCSS Regina Elena National Cancer Institute, Rome 00144, Italy.

Introduction: Due to their high stability in body fluids, circulating tumor microRNAs are proposed as
promising biomarkers useful for early tumor diagnosis, prognosis, monitoring, and to predict therapeutic
response, in non-invasive liquid biopsy. We investigated the release of miR-141-3p, miR-221-3p and miR-222-
3p previously associated to colorectal cancer (CRC).

Experimental model: We employed droplet digital PCR to quantify the amount of miRNAs released in:
(1) supernatants of three human CRC cell lines (HT-29, LoVo and Ls174T); (2) in plasma of nude mice
inoculated with the same three cell lines, in order to obtain tumor xenograft models; (3) in plasma isolated
from a heterogeneous group of CRC patients.

Results: MicroRNAs miR-221-3p and miR-222-3p (but not miR-141) in cellular supernatants were
proportional to the cellular levels. Interestingly, all three miRNAs are released in plasma of xenografted
mice. Using plasma samples from CRC patients, we found that only in 57% of the cases it was possible to
identify a differential expression of at least one of the miRNAs with respect to control subjects.

Conclusion: Our data demonstrate that, despite the three selected miRNAs are not only present in CRC
cells and tissues but are also released in extracellular environments, they are not informative for a high
proportion of CRC patients. NGS allowed to expand the number of miRNAs differentially expressed in CRC
samples. A novel set, constituted of 12 miRNA was demonstrated to be of diagnosis relevance in 94% of CRC
patients samples (funded by AIRC IG13575 and Horizon 2020 Project ULTRAPLACAD).

26. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic
germline variants in BAP1 or other DNA repair genes

1*
1
4
2
3
1*
Marika Sculco , Marta Betti , Anna Aspesi , Daniela Ferrante , Luisella Righi , Dario Mirabelli ,
8
6,7
Francesca Napoli , Milena Rondón-Lagos , Elisabetta Casalone , Francesca Vignolo Lutati ,
5
3
Paola Ogliara , Paolo Bironzo , Laura Cristina Gironi , Paola Savoia , Antonella Maffè , Silvana
1
1
9
10
8
11
10
14
12
Ungari , Federica Grosso , Roberta Libener , Renzo Boldorini , Michele Valiante , Barbara
13
Pasini , Giuseppe Matullo 6,7,8 , Giorgio Scagliotti , Corrado Magnani , Irma Dianzani 1
9
2
8
1 Department of Health Sciences, University of Piemonte Orientale, Novara 28100, Italy.
2 Unit of Cancer Epidemiology, CPO-Piemonte, Department of Translational Medicine, University of Piemonte
Orientale, Novara 28100, Italy.
3 Department of Oncology, University of Turin at San Luigi Hospital, Orbassano 10043, Italy.
4 Unit of Cancer Epidemiology, CPO-Piemonte and University of Turin, Turin 10126, Italy.
5 Escuela de Ciencias Biológicas, Universidad Pedagógica y Tecnológica de Colombia, Tunja 39-115, Colombia.
6 Department of Medical Sciences, University of Turin, Turin 10126, Italy.
7 Italian Institute for Genomic Medicine, Turin 10126, Italy.
8 Medical Genetics Unit, AOU Città della Salute e della Scienza, Turin 10126, Italy.
9 Department of Oncology, University of Turin, Turin 10126, Italy.
10 Molecular Genetics and Biology Unit, Santa Croce e Carle Hospital, Cuneo 12100, Italy.
11 Division of Medical Oncology, SS. Antonio e Biagio General Hospital, Alessandria 15121, Italy.
12 Pathology Unit, SS. Antonio e Biagio General Hospital, Alessandria 15121, Italy.
13 Department of Health Sciences, Section of Pathological Anatomy, University of Piemonte Orientale, Novara
28100, Italy.
14 Clinical Genetics Unit, AO San Camillo-Forlanini, University La Sapienza, Rome 00185, Italy.